Ono Pharmaceutical Co., Bristol-Myers Squibb Co., and Kyowa Hakko Kirin Co. have entered into a clinical trial collaboration to conduct a Phase I combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study will be conducted in Japan and will evaluate the safety, tolerability and anti-tumor activity of the combination as a potential treatment for advanced or metastatic solid tumors.   Opdivo, launched in Japan in September 201...